Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial

M. P. Goetz*, N. A. Bagegni, G. Batist, A. Brufsky, M. A. Cristofanilli, S. Damodaran, B. R. Daniel, G. F. Fleming, W. J. Gradishar, S. L. Graff, M. T. Grosse Perdekamp, E. Hamilton, S. Lavasani, A. Moreno-Aspitia, T. O'Connor, T. J. Pluard, H. S. Rugo, S. L. Sammons, L. S. Schwartzberg, D. G. StoverG. A. Vidal, G. Wang, E. Warner, R. Yerushalmi, P. V. Plourde, D. J. Portman, E. N. Gal-Yam

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Fingerprint

Dive into the research topics of 'Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial'. Together they form a unique fingerprint.

INIS

Pharmacology, Toxicology and Pharmaceutical Science